Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis
The application of STING agonists and the blockade of the SIRPα–CD47 signaling axis are emerging immunotherapeutic strategies. Here the authors show that hybrid cellular membrane nanovesicles loaded with a STING agonist or overexpressing high-affinity SIRPα variants can be exploited to promote anti-...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f17de9f800584c86b4d4c951356870bb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:f17de9f800584c86b4d4c951356870bb |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:f17de9f800584c86b4d4c951356870bb2021-12-02T17:18:07ZHybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis10.1038/s41467-020-18626-y2041-1723https://doaj.org/article/f17de9f800584c86b4d4c951356870bb2020-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18626-yhttps://doaj.org/toc/2041-1723The application of STING agonists and the blockade of the SIRPα–CD47 signaling axis are emerging immunotherapeutic strategies. Here the authors show that hybrid cellular membrane nanovesicles loaded with a STING agonist or overexpressing high-affinity SIRPα variants can be exploited to promote anti-tumor immune responses.Lang RaoLei WuZhida LiuRui TianGuocan YuZijian ZhouKuikun YangHong-Gang XiongAnli ZhangGuang-Tao YuWenjing SunHan XuJingya GuoAndrew LiHongmin ChenZhi-Jun SunYang-Xin FuXiaoyuan ChenNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-13 (2020) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Science Q |
spellingShingle |
Science Q Lang Rao Lei Wu Zhida Liu Rui Tian Guocan Yu Zijian Zhou Kuikun Yang Hong-Gang Xiong Anli Zhang Guang-Tao Yu Wenjing Sun Han Xu Jingya Guo Andrew Li Hongmin Chen Zhi-Jun Sun Yang-Xin Fu Xiaoyuan Chen Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis |
description |
The application of STING agonists and the blockade of the SIRPα–CD47 signaling axis are emerging immunotherapeutic strategies. Here the authors show that hybrid cellular membrane nanovesicles loaded with a STING agonist or overexpressing high-affinity SIRPα variants can be exploited to promote anti-tumor immune responses. |
format |
article |
author |
Lang Rao Lei Wu Zhida Liu Rui Tian Guocan Yu Zijian Zhou Kuikun Yang Hong-Gang Xiong Anli Zhang Guang-Tao Yu Wenjing Sun Han Xu Jingya Guo Andrew Li Hongmin Chen Zhi-Jun Sun Yang-Xin Fu Xiaoyuan Chen |
author_facet |
Lang Rao Lei Wu Zhida Liu Rui Tian Guocan Yu Zijian Zhou Kuikun Yang Hong-Gang Xiong Anli Zhang Guang-Tao Yu Wenjing Sun Han Xu Jingya Guo Andrew Li Hongmin Chen Zhi-Jun Sun Yang-Xin Fu Xiaoyuan Chen |
author_sort |
Lang Rao |
title |
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis |
title_short |
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis |
title_full |
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis |
title_fullStr |
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis |
title_full_unstemmed |
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis |
title_sort |
hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis |
publisher |
Nature Portfolio |
publishDate |
2020 |
url |
https://doaj.org/article/f17de9f800584c86b4d4c951356870bb |
work_keys_str_mv |
AT langrao hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT leiwu hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT zhidaliu hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT ruitian hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT guocanyu hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT zijianzhou hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT kuikunyang hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT honggangxiong hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT anlizhang hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT guangtaoyu hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT wenjingsun hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT hanxu hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT jingyaguo hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT andrewli hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT hongminchen hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT zhijunsun hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT yangxinfu hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis AT xiaoyuanchen hybridcellularmembranenanovesiclesamplifymacrophageimmuneresponsesagainstcancerrecurrenceandmetastasis |
_version_ |
1718381176964513792 |